The World Health Organization (WHO) has warned that children, pregnant women and people with weak immune systems are at higher risk from the mpox outbreak in the Democratic Republic of Congo ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
The Cell & Gene Therapy manufacturing Services market is driven by increasing investments in advanced therapies, rising ...
MyChesCo on MSN13d
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming ConferenceOcugen, Inc. (NASDAQ: OCGN) has announced that its Chief Scientific Officer, Dr. Arun Upadhyay, will be a featured speaker at ...
GlobalData on MSN16d
RegenxBio touts positive data for rare disease drug RGX-121RGX-121 has been evaluated in the Phase I/II/III CAMPSIITE study as a one-time gene therapy treatment for Hunter syndrome.
D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...
Pathway to Professional Nursing is a novel partnership between the UAB School of Nursing and Birmingham City Schools developed to address the nursing workforce shortage in Birmingham and throughout ...
The tool identifies high-risk patients, creates care pathways, and alerts doctors, nursing staff, and palliative care teams ...
AAV-AQP1 is a gene therapy commercialized by MeiraGTx, with a leading Phase II program in Sicca Syndrome (Sjogren).
Can you stop LCA, a form of blindness caused by a change in a single base pair, simply by injecting a viral vector with the right ... indicated that the visual pathway indeed retains the ability ...
FLT-201 is a gene therapy commercialized by Spur Therapeutics, with a leading Phase II program in Gaucher Disease Type I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback